Artiva Biotherapeutics (NASDAQ:ARTV) Shares Up 6.2%

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) rose 6.2% during trading on Friday . The company traded as high as $12.56 and last traded at $12.46. Approximately 2,882,696 shares changed hands during mid-day trading, an increase of 1,506% from the average daily volume of 179,512 shares. The stock had previously closed at $11.73.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Cantor Fitzgerald assumed coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They set an “overweight” rating and a $23.00 target price for the company. Jefferies Financial Group began coverage on Artiva Biotherapeutics in a research note on Tuesday, August 13th. They set a “buy” rating and a $21.00 price objective for the company. Wedbush reiterated an “outperform” rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a research note on Friday, August 30th. TD Cowen started coverage on shares of Artiva Biotherapeutics in a report on Tuesday, August 13th. They set a “buy” rating for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Friday, August 30th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $21.25.

Artiva Biotherapeutics Stock Up 6.2 %

The business’s 50-day moving average is $11.27.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings results on Thursday, August 29th. The company reported ($19.10) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($18.03). As a group, research analysts forecast that Artiva Biotherapeutics, Inc. will post -4.6 EPS for the current year.

Insider Activity at Artiva Biotherapeutics

In other Artiva Biotherapeutics news, major shareholder Global Strategic Fund I. Venbio acquired 416,666 shares of the stock in a transaction dated Monday, July 22nd. The shares were bought at an average price of $12.00 per share, with a total value of $4,999,992.00. Following the purchase, the insider now directly owns 1,936,637 shares of the company’s stock, valued at approximately $23,239,644. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, major shareholder Global Strategic Fund I. Venbio bought 416,666 shares of the firm’s stock in a transaction that occurred on Monday, July 22nd. The shares were acquired at an average cost of $12.00 per share, for a total transaction of $4,999,992.00. Following the acquisition, the insider now directly owns 1,936,637 shares of the company’s stock, valued at approximately $23,239,644. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Yong-Jun Huh bought 2,083,332 shares of the business’s stock in a transaction dated Monday, July 22nd. The shares were bought at an average cost of $12.00 per share, for a total transaction of $24,999,984.00. Following the completion of the transaction, the director now directly owns 3,306,900 shares of the company’s stock, valued at $39,682,800. The disclosure for this purchase can be found here.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.